- 2 days ago
- 8 min read
Updated: 6 hours ago
Table of Content:
|
A Quick Tour of CAR-T Immunotherapy in 2026
In just nine years, FDA approved CAR T cell therapies — the engineered chimeric antigen receptor T cells that have transformed treatment of aggressive blood cancers — have moved from experimental science to standard of care. As of 2026, six FDA approved CAR T cell products are available in the United States, each engineered to target a specific protein on cancer cells and each carrying its own profile of advantages, approved indications, and costs.
For patients and families facing a complex relapse or refractory diagnosis, choosing among these therapies — or deciding whether to also evaluate international options — starts with understanding what each product actually does. This guide breaks down all six FDA approved CAR T cell therapies, the differences between them, and what they cost in 2026.
The Six FDA Approved CAR T Cell Therapies at a Glance
The six FDA approved CAR T cell products split into two target families. The table below shows each product's sponsor, target antigen, approval year, primary indications, and unique clinical advantage relative to its peers.
Product | Sponsor | Target / Year | Primary Indications | Key Advantage |
Kymriah (tisagenlecleucel) | Novartis | CD19 / 2017 | B-ALL (up to age 25), DLBCL, follicular lymphoma | Longest safety record; only CAR-T approved for pediatric/young adult B-ALL |
Yescarta (axicabtagene ciloleucel) | Gilead/Kite | CD19 / 2017 | LBCL (2L+), follicular lymphoma | Strongest long-term LBCL data: 32% 5-year OS overall, 56% in responders |
Tecartus (brexucabtagene autoleucel) | Gilead/Kite | CD19 / 2020 | Mantle cell lymphoma, adult B-ALL | Only CAR-T approved for mantle cell lymphoma and adult B-ALL |
Breyanzi (lisocabtagene maraleucel) | BMS | CD19 / 2021 | LBCL, CLL/SLL, follicular lymphoma, mantle cell lymphoma | Broadest CD19 portfolio; 97% ORR / 94% CR in TRANSCEND FL |
Abecma (idecabtagene vicleucel) | BMS / 2seventy | BCMA / 2021 | Relapsed/refractory multiple myeloma | First BCMA CAR-T approved; established myeloma option |
Carvykti (ciltacabtagene autoleucel) | Janssen/Legend | BCMA / 2022 | Relapsed/refractory multiple myeloma | Strongest myeloma durability: ~1/3 PFS at 5 years (CARTITUDE-1) |
According to a 2025 Frontiers in Immunology registry analysis, CD19 accounts for about 54% of all global CAR-T trials, while BCMA is second at 16%. In 2025, the FDA also removed REMS reporting requirements for all six products and lifted the rule that hospitals must keep onsite tocilizumab — a major signal of regulatory confidence in CAR T immunotherapy after nearly a decade of real-world use.
CD19-Targeted Products: Strengths and Approved Indications
Kymriah (tisagenlecleucel, Novartis) was the first FDA approved CAR T cell therapy, cleared in 2017. It is indicated for B-cell acute lymphoblastic leukemia (B-ALL) in patients up to 25 years old, plus relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma in adults. Its strength: the longest real-world safety record among approved products.
Yescarta (axicabtagene ciloleucel, Gilead/Kite) was approved in 2017 for large B-cell lymphoma (LBCL) and later expanded to follicular lymphoma. A 2025 five-year follow-up from OHSU showed overall survival of 32% across all infused patients and 56% among responders — durable, cure-level data for many.
Tecartus (brexucabtagene autoleucel) is approved for mantle cell lymphoma and adult B-ALL.
Breyanzi (lisocabtagene maraleucel) has the broadest CD19 indication portfolio: LBCL, chronic lymphocytic leukemia (CLL), follicular lymphoma, and mantle cell lymphoma. ASH 2025 data from the TRANSCEND FL trial showed Breyanzi achieved a remarkable 97% response rate and 94% complete response rate in heavily pretreated follicular lymphoma patients at three years of follow-up.
BCMA-Targeted Products and Multiple Myeloma
For multiple myeloma, Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel) target BCMA on plasma cells. Both have transformed outcomes for patients who have exhausted previous lines of therapy.
The 2025 ASCO update of the CARTITUDE-1 trial for Carvykti showed roughly one-third of heavily pretreated multiple myeloma patients remained alive and progression-free at five years after a single infusion. This is a profound shift in a disease historically considered incurable. As Dr. Mazyar Shadman of Fred Hutch Cancer Center put it in a December 2025 interview:
"CAR T has been so effective against lymphoma, multiple myeloma, and certain leukemias that patients with these diseases should seek out a CAR T expert if they experience a relapse."
2026 Costs of FDA Approved CAR T Cell Therapy
Drug list prices (wholesale acquisition cost, or WAC) for the six FDA approved CAR T cell therapies range from approximately $373,000 to $475,000. But the drug itself is only part of the bill — total cost of care depends on hospitalization, complication management, and the inpatient vs. outpatient setting.
Product | Approx. Drug List Price | Indication Setting | Total Cost (typical) |
Kymriah (B-ALL) | ~$475,000 | Pediatric/young adult B-ALL | $600K – $1M+ (high-monitoring) |
Kymriah (DLBCL) | ~$373,000 | Adult DLBCL | $500K – $800K |
Yescarta | ~$373,000 | LBCL / follicular lymphoma | $500K – $850K |
Tecartus | ~$373,000 | Mantle cell / adult B-ALL | $520K – $900K |
Breyanzi | ~$410,000 | LBCL, CLL, FL, MCL | $500K – $750K (outpatient-eligible) |
Abecma | ~$419,500 | Multiple myeloma | $550K – $900K |
Carvykti | ~$465,000 | Multiple myeloma | $600K – $1M+ |
Across all six products, the median commercial total cost is approximately $608,100, and roughly 8.5% of patients exceed $1 million in total expenses, per AJMC analyses. For a full global cost breakdown including lower alternative treatment destinations, see our companion piece on CAR T cell therapy price in 2026.
Lower-Cost Alternatives Abroad — How China Has Reshaped CAR-T Access
For patients facing $500,000-$1,000,000+ in total CAR-T costs in the US, the cost spread between approved products matters less than the cost spread between countries. China has emerged as the lowest-cost destination for clinically equivalent CAR-T therapy — and is now a serious option for international patients and US patients without comprehensive insurance coverage.
Commercial CAR-T in China typically costs $120,000-$220,000 total, including the drug, hospitalization, and supportive care — a 50-70% reduction versus the US median. For patients who qualify for an Investigator-Initiated Trial (IIT), total costs can drop further: $40,000-$60,000 with the cell product often provided at no charge, or as little as $15,000-$25,000 for selected patients in qualifying protocols.
China's cost advantage rests on three structural factors:
Lower facility and labor costs at top hematology centers in Beijing, Shanghai, and Tianjin.
Six NMPA-approved domestic CAR-T products (Carteyva, Fucaso, and others) that compete with US-licensed imports — driving prices down through real market competition.
Faster manufacturing: next-generation automated platforms compress vein-to-vein time to 24-36 hours at leading centers, versus 3-5 weeks in the US — also reducing inpatient days and bridging-therapy costs.
Quality concerns are reasonable but answerable. Many of China's leading cancer hospitals are JCI-accredited and formally partnered with US institutions like Mass General (Harvard) and Mayo Clinic — the same gold-standard accreditation framework used at top US hospitals. For a complete cross-country pricing picture, see our CAR T cell therapy price 2026 global breakdown, and for a deeper look at the Chinese landscape, our CAR-T immunotherapy in China guide.
Case Study: Lane’s Complete Remission After CAR-T
Lane, a patient profiled by Dana-Farber Cancer Institute in September 2025, illustrates what a successful FDA approved CAR T cell therapy outcome looks like. After standard front-line treatment for multiple myeloma followed by relapse, she received CAR-T in May 2025.
Within months, Lane was in complete remission with no detectable disease — and just as importantly, she did not require ongoing maintenance therapy. As she described it, the "one-and-done" nature of the treatment gave her back her time, energy, and independence. Stories like Lane’s underscore why CAR T immunotherapy has become a first-line consideration in many relapse scenarios.
Key Takeaways
Six FDA approved CAR T cell therapies are available in 2026: four CD19-targeted (Kymriah, Yescarta, Tecartus, Breyanzi) and two BCMA-targeted (Abecma, Carvykti).
The 2025 REMS reporting removal has expanded community access and outpatient delivery.
Long-term efficacy data are strong — 97% response rate in some follicular lymphoma cohorts and 5-year progression-free survival in roughly one-third of treated myeloma patients.
US total treatment costs range from approximately $499,000 to over $1 million per patient.
International alternatives such as China can reduce costs by 50-70% while preserving clinical quality and meaningful regulatory oversight.
Schedule a Pre-Treatment Telehealth Consultation
If you or a loved one is weighing options among FDA approved CAR T cell therapies — or wondering whether a globally approved alternative makes more sense — a virtual consultation is the safest first step. Telehealth lets you review medical records with our partner clinicians, compare US and international pathways, and avoid unnecessary travel for evaluation alone.
International CAR-T destinations are increasingly held to the same quality standards as US institutions — China alone has 46 JCI accredited hospitals with formal partnerships with Mass General, Mayo Clinic, and other top US academic centers, giving international patients verifiable assurance before they travel.
About ChinaCureLink (Medebound HEALTH): Founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific. Contact us below for free medical record review.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Conclusion
Nine years after the first FDA approved CAR T cell therapy, the field is mature, the evidence is strong, and the patient experience is steadily improving. With six products, expanding indications, and growing outpatient access, more families have realistic curative options than ever before.
For an overview of the broader CAR T immunotherapy landscape — including how China is changing global access — visit our guide to CAR-T immunotherapy in China, or read more about pricing in our global cost breakdown. To explore a personalized treatment plan, visit ChinaCureLink.
About ChinaCurelink
ChinaCurelink helps patients across Southeast Asia — including Indonesia, Malaysia, the Philippines, Vietnam, and Thailand — access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top 5 cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team that understands both the medical and cultural needs of Southeast Asian patients.
ChinaCurelink is proudly affiliated with Medebound HEALTH— an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia Pacific, Medebound HEALTH brings the same standard of expert care coordination to every patient we serve.